invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines
Retrieved on:
Thursday, June 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nanoparticle, Workforce Investment Act of 1998, Infection, Cancer, Temperature, Prostate, Dicarboxylic acid, Messenger, CD8, SaRNA, Sino Biopharmaceutical Limited, HKEX, Trust, HPV-positive oropharyngeal cancer, Patient, RALA, HPV, Growth, Cervical cancer, Therapy, Vaccine
invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.
Key Points:
- invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.
- The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response.
- Prof. Helen McCarthy, Chief Executive Officer and Founder of pHion, said:
“At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA. - We look forward to seeing PTX_V1 reach the clinic and supporting this program into the next stages of its development.”